MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Sarcomatoid

Less common than epithelioid mesothelioma, only 7% to 20% of mesothelioma are sarcomatoid. Often called the “wild” type because of it’s unpredictable nature.

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Lung Cancer 2018 November [Link] Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K Abstract OBJECTIVES: Histologic diagnosis of malignant pleural mesothelioma (MPM) is not always straightforward. Loss of BRCA1-associated protein 1 (BAP1) expression as detected by immunohistochemistry (IHC) (BAP1 IHC) and […]

Comments Off on A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma.

Annals of Thoracic Surgery 2018 October 30 [Link] Harling L, Kolokotroni SM, Nair A, Smelt J, King J, Routledge T, Spicer J, Ng W, Bille A Abstract BACKGROUND: Biphasic mesothelioma (BPM) accounts for approximately 10% of all pleural mesothelioma. Our aim was to assess the clinical, radiological and pathological factors impacting survival in BPM and […]

Comments Off on Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma.

[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].

Revue de Pneumologie Clinique 2018 October 4 [Link] Mlika M, Lamzirbi O, Limam M, Mejri N, Ben Saad S, Chaouch N, Ben Miled K, Marghli A, Mezni F Abstract BACKGROUND: The malignant pleural mesothelioma (MPM) is a rare tumour usually associated to asbestos exposure. The delay between the exposure and the occurrence of the cancer […]

Comments Off on [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].

Is There a Role for Cancer Directed Surgery in Early Stage Sarcomatoid or Biphasic Mesothelioma?

The Annals of Thoracic Surgery 2018 September 29 [Link] Kim S, Bull DA, Garland L, Khalpey Z, Stea B, Yi S, Hsu CC Abstract BACKGROUND: Benefits of surgery for early stage non-epithelioid MPM have not been clearly elucidated. This study investigated whether cancer-directed surgery affects overall survival compared to non-surgical therapies for T1-T2N0M0 sarcomatoid or […]

Comments Off on Is There a Role for Cancer Directed Surgery in Early Stage Sarcomatoid or Biphasic Mesothelioma?

Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Clinical Lung Cancer 2018 September 3 [Link] Fodor A, Broggi S, Incerti E, Dell’Oca I, Fiorino C, Samanes Gajate AM, Pasetti M, Cattaneo MG, Passoni P, Gianolli L, Calandrino R, Picchio M,

Comments Off on Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

What’s new in mesothelioma

Pathologica 2018 March [Link] Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L Abstract Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. Diagnosis, prognosis and therapy are often challenging and include several issues. Cytological diagnosis is frequently the first […]

Comments Off on What’s new in mesothelioma

Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Clinical Lung Cancer 2018 August 29 [Link] Verma V, Ahern CA, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone Abstract INTRODUCTION: For the 3 histologic subtypes of malignant pleural mesothelioma (MPM)-epithelioid, sarcomatoid, and biphasic-the magnitude of benefit with surgical management remains underdefined. MATERIALS AND METHODS: The National Cancer […]

Comments Off on Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Aquaporin-1 (AQP-1) expression in fluoro-edenite-induced mesothelioma effusions: an approach by cell-block procedure

Cytopathology 2018 June 6 [Link] Angelico G, Ieni A, Caltabiano R, Zeppa P, Tuccari G Abstract OBJECTIVE: Aquaporin 1 (AQP-1) is a water channel protein found in cell membranes, whose expression has been considered an independent favourable prognostic factor in pleural Malignant Mesothelioma (MM). The aim of this study is to evaluate the expression of […]

Comments Off on Aquaporin-1 (AQP-1) expression in fluoro-edenite-induced mesothelioma effusions: an approach by cell-block procedure

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

Modern Pathology 2018 May 21 [Link] Chiu K, Lee L, Cheung S, Churg AM Abstract Immunohistochemistry (IHC) is used to help differentiate pleural mesothelioma from pulmonary adenocarcinoma in pleural biopsies and cytology specimens of pleural effusions due to overlapping morphologic features between these two malignancies. The aim of this study is to evaluate IHC glypican-1, […]

Comments Off on Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Carcinogenesis 2018 April [Link] Schelch K et.al Abstract Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelial-mesenchymal transition (EMT) and […]

Comments Off on FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal